Showing Results for
- Academic Journals (74)
Search Results
- 74
Academic Journals
- 74
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Jeff Fox During a three-day expanded session of the US National Institutes of Health (NIH; Bethesda, MD) Recombinant DNA Advisory Committee (NIHRAC) in December, committee members and officials of NIH and...
- 2From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Asako Saegusa [1] Proteomics is at last making an appearance on Japan's national agenda: For the first time, protein-related research has been targeted by the government--in its most recent supplementary...
- 3From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): John Hodgson Biotechnology has achieved much in the past two decades. Protein drugs have proved effective enough replacements for missing or defective molecules in conditions such as diabetes, pituitary...
- 4From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Eric Niiler A US federal judge has ruled that a key patent for an enzyme used in a DNA analysis technique is invalid and was obtained by fraud. The patent at issue--the '818 Taq patent--covers the native and...
- 5From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Jeff Fox The lawfirm of Cohen, Milstein, Hausfeld and Toll has filed a lawsuit in US federal court against Monsanto (St. Louis, MO) on behalf of farmers in the US and internationally. Longtime biotechnology...
- 6From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Jeff Fox November marked the settlement of two major biotechnology patent disputes. In one, Genentech (South San Francisco, CA) agreed to provide the University of California (Berkeley, CA) with $200 million...
- 7From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Toshiki Tamura [1]; Chantal Thibert [2]; Corinne Royer [3]; Toshio Kanda [1]; Abraham Eappen [1]; Mari Kamba [1]; Natuo Kômoto [1]; Jean-Luc Thomas [3]; Bernard Mauchamp [3]; Gérard Chavancy [3]; Paul Shirk...
- 8From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Eric Niiler [1] Life science rivals AstraZeneca (London) and Novartis (Basel, Switzerland) announced in early December that they plan to spin off and merge their agrochemical divisions. Although the move...
- 9From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): John Hodgson A report circulated privately in December to officials at the European Commission warns that final negotiations to implement measures within the United Nations Convention on Biological Diversity...
- 10From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Fiona Grüninger-Leitch [1]; Peter Berndt [2]; Hanno Langen [2]; Peter Nelboeck [1]; Heinz Döbeli (corresponding author) [1] The selective cleavage of a large protein substrate by a protease requires...
- 11From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Henry I. Miller [1] To the editor: In his letter about what constitutes appropriate demeanor and decorum for discussions of public policy, Edward Groth III, director of technical policy and public service...
- 12From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Alan Dove Using transformed cell lines derived from the three main layers of human corneas, researchers in Canada and the US have constructed artificial corneas in vitro that appear to mimic the natural...
- 13From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Ambuj Sagar [1]; Arthur Daemmrich [1]; Mona Ashiya [2] In pluralistic societies, innovations offering new ways to promote independence or individuality are generally rapidly embraced, whereas those that...
- 14From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Zhiwen Zhang [1]; Weiguang Zhu [1]; Thomas Kodadek (corresponding author) [1] Antibodies are extremely useful molecules in medical diagnostics, biotechnology, and biomedical research because of their ability...
- 15From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Alan Dove In November, Isis Pharmaceuticals (Carlsbad, CA) announced the departure of its longstanding partner, Novartis Pharmaceuticals (Basel, Switzerland), leaving the small biotech company to underwrite...
- 16From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Theo Thepen (corresponding author) [1, 2]; A. J. Hanneke van Vuuren [1]; Rebecca C. M. Kiekens [3]; Cora A. Damen [1]; Wim C. Vooijs [4]; Jan G. J. van de Winkel [1, 2] The skin serves as an important...
- 17From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): John Hodgson * Baptist pro-biotech demonstrators at the US Food and Drug Administration in Washington in December carried placards reading "Biotech saves children's lives" and "Biotech equals jobs." Their...
- 18From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedWhen you consider that we look and sometimes behave much as our hunter-gatherer forebears did, it seems fair to say that as a robust means of transmitting information through millennia, DNA can't be beat. By contrast,...
- 19From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): Alan Dove Computer giant IBM has announced a $100 million initiative to build the world's fastest supercomputer, developing an entirely new computer architecture that IBM says will be designed specifically...
- 20From: Nature Biotechnology. (Vol. 18, Issue 1) Peer-ReviewedAuthor(s): John Hodgson; Marshall As you write all four digits of the year wrongly on your checks for the first time for a 1000 years, its good to know that some things never change. Once again, its time for...